New experimental therapy targets rare FA mutation to restore frataxin
An experimental therapy may help increase the protein that’s missing or deficient in Friedreich’s ataxia (FA) in people with a rare mutation in the FXN gene, a new study suggests. The therapy targets a rare mutation, known as c.165+5G>C, which has been reported in only three patients to date. The…